u/source_or_silence

Has appetite changed yet, independent of the scale?

Most of what gets posted here is procedural rather than dramatic: a step skipped, a document not requested, a temperature not considered, a pace chosen out of impatience.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

Powder or already in solution?

Adding the practical version: ask which lines are held regionally before you order in July.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

no clinical trial has established what these threads assert

Do sulphur burps track the day after the shot, or is it there all week?

Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.

Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.

What do you think the glucagon component is adding, specifically?

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

The evidence base, described honestly, which almost no summary of it does.

The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.

That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.

The three questions, kept separate, because this board runs them together constantly.

Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.

A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.

Put a logger in three consecutive orders. Two never went above the range at all and the third spent four hours warm on a Friday. Cost me almost nothing to stop wondering.

Yes — a logger in the box turns a fortnight of speculation into a chart.

research-use-only material is not approved for human use, full stop

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

What method produced that purity number?

The standing caveat, written out properly because it keeps getting compressed into a footnote.

Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.

What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.

What I would tell week-one me, in order of how much time it would have saved.

One: the first month is a tolerance check. You are finding out whether you can take this, not how much you will lose. Two: write down the dose, the day and the waist measurement. Three: a stall of under six weeks is weather, not climate. Four: early fullness that arrives the day after the shot and fades by day four is the ordinary pattern and it usually settles at a stable dose.

None of that is advice about what you should do. It is the shape of the thing, which nobody explained to me and which the wiki explains better than I just did.

Correction: that stability figure covers the lyophilised powder, not the reconstituted solution. Different claim entirely.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

Minor fix — the half-life is about a week, not about a day.

Adding one thing to this: the appetite effect and the scale run on separate clocks, so both halves can be true at once.

Sceptical of the mechanism you are proposing. Gastric emptying slows, it does not stop, and the timings you describe do not follow from it.

dose day drift of a day either way is fine, the curve barely notices

the appetite signal and the scale move on different clocks

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.